apoC-III
Foxo1 mediates insulin action on apoC III and triglyceride metabolism
... on apoC-III and TG metabolism in ...hepatic apoC-III production and plasma TG metabolism in vivo, we transferred Foxo1 cDNA into liver of ...
12
Sex differences in HDL ApoC-III in American Indian youth
... increased apoC-III relative to apoA-I, could result in adverse functional ...non-HDL apoC-III in relation to insu- lin resistance in Cherokee Indian adolescents [23], HDL ...
7
<p>Higher Plasma APOC-III Was Associated with a Slower Reduction of β-Amyloid Levels in Cerebrospinal Fluid Among Older Individuals Without Dementia</p>
... plasma APOC-III levels (categorized as tertiles) with changes in CSF AD biomarkers over time, linear mixed models were fi ...plasma APOC-III were associated with changes in CSF A β 42, but not ...
6
ApoC-III and visceral adipose tissue contribute to paradoxically normal triglyceride levels in insulin-resistant African-American women
... and apoC-III ...only apoC- III and VAT were significant determinants of the TG concentration in both light and dense ...low apoC-III ...
10
ApoC III inhibits clearance of triglyceride rich lipoproteins through LDL family receptors
... ity measurements were normalized for the initial tissue weights. Ultracentrifugation. Plasma was pooled from several mice (70 μl/ mouse, n = 3–5 mice/genotype). Lipoprotein fractions were separated by buoyant density ...
13
Apolipoproteins as Differentiating and Predictive Markers for Assessing Clinical Outcomes in Patients with Small Cell Lung Cancer
... anti-ApoE, ApoC-III, and ApoA- 1, diluted 100, 100, and 200 times, respectively; Abcam, Cam- bridge, United Kingdom) for 2–3 hours at room temperature, and then rinsed three times with PBS for 5 minutes ...
8
Mining Genomic Variants And Causal Pathways Linking Hdl And Triglycerides To Coronary Disease
... Like ApoC-III, ApoA-V exchanges between HDLs and TRLs and is primarily secreted from the liver. A 39 kDa protein, ApoA-V has a very low concentration in human plasma (~150 ng/ml) [107]. Despite this, ApoA-V ...
316
Apolipoprotein C III 1 activates lysosomal sphingomyelinase in vitro
... Apolipoprotein (apo)C-III-1 from human very low density lipoprotein stimulates 14-fold the activity of lysosomal sphingomyelinase from human fibroblasts. At the sphingomyelin concentrations tested, maximal ...
6
Mass spectrometry-based approaches to targeted quantitative proteomics in cardiovascular disease
... AI; ApoC-III: apolipo- protein CIII; CE: cholesteryl ester; CETP: cholesteryl ester transfer protein; CHD: coronary heart disease; CRP: C-reactive protein; CV: coefficient of variation; ELISA: enzyme-linked ...
18
Associations between epicardial adipose tissue, subclinical atherosclerosis and high-density lipoprotein composition in type 1 diabetes
... gender, age, hypertension, dyslipidemia, smoking, body mass index, waist circumference, insulin dose, and triglycer‑ ide (P < 0.05). The iEAT correlated positively with small HDL, increased content of apolipoprotein ...
10
Human ApoA II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice
... hypertriglyceridemia). CETP expression resulted in reductions of HDL and increases in VLDL cholesteryl ester in mice expressing human apoA-II, alone or in combination with apoA-I and apoC-III, indicating ...
12
Modulation of lipoprotein lipase activity by apolipoproteins Effect of apolipoprotein C III
... the ApoC-III or apolipoprotein E ...of ApoC-III on LPL activity. The addition of ApoC-III-2 resulted in a decreased rate of lipolysis of human very low density lipoproteins by ...
8
Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline: a longitudinal study
... between apoC-III and eGFR slope, but again it utilized a very different study population consisting of 73 non-diabetic adults who had primary renal disease due to glomerular disease, polycystic kidney ...
8
Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA)
... B; apoC- III: Apolipoprotein C-III; CAD: Coronary artery disease; CHD: Coronary heart disease; CHERRY: Combination Therapy of Eicosapentaenoic Acid and Pitavastatin for Coronary Plaque Regression ...
13
D25V apolipoprotein C III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile
... syndrome; ApoC-III amyloid confirmed histologically; decreased plasma triglyceride levels; no clinical syndrome, no amyloid on histology, absence of APOC3 mutation, no ...the apoC-III ...
15
Progress on elimination of lymphatic filariasis in Sierra Leone
... positives-only; APOC: African Programme for Onchocerciasis Control; CDD: Community-directed drug distributor; CDTI: Community-directed treatment with ivermectin; CI: Confidence interval; CNTD: Centre for Neglected ...
10
The need for evidence-based strategies and tools for onchocerciasis elimination in Africa
... similar to the Onchocerciasis Control Programme in West Africa (OCP) framework for vector control that was developed and operationally used at scale by OCP in the 1980s. However, this vector control model is not valid ...
5
iTRAQ-based proteomic analysis of the reproductive cycle characteristics of Hainan Black Goat, the unique species in China, Hainan Province
... As apoC-II is a small exchangeable apolipoprote on triglyceride-rich lipoproteins (Wolska et ...of apoC-II in oestrum reduced to ...of apoC-II protein up-regulated to the ratio of ...
12
Compliance with eight years of annual ivermectin treatment of onchocerciasis in Cameroon and Nigeria
... The study was designed to determine rates of compli- ance to and perceived benefits of annual ivermectin treatment for the control of onchocerciasis in five APOC supported project sites in Cameroon and Nigeria. ...
7
Implementation of test and treat with doxycycline and temephos ground larviciding as alternative strategies for accelerating onchocerciasis elimination in an area of loiasis co endemicity: the COUNTDOWN consortium multi disciplinary study protocol
... Onchocerciasis (river blindness) is a vector-borne, neglected tropical disease (NTD), caused by the filarial parasite Onchocerca volvulus. Physical manifestations include troublesome itching, skin rash, visual impair- ...
13